OTCMKTS:INBP Integrated BioPharma (INBP) Stock Price, News & Analysis $0.28 0.00 (0.00%) As of 08/8/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Integrated BioPharma Stock (OTCMKTS:INBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Integrated BioPharma alerts:Sign Up Key Stats Today's Range$0.28▼$0.2850-Day Range$0.26▼$0.3652-Week Range$0.16▼$0.42VolumeN/AAverage Volume11,403 shsMarket Capitalization$8.67 millionP/E Ratio7.00Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Read More Receive INBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Integrated BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address INBP Stock News HeadlinesINBP Integrated BioPharma, Inc.June 15, 2025 | seekingalpha.comIntegrated BioPharma Secures New Credit Line with PNCApril 21, 2025 | tipranks.comAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump policy move, and the other tied to a proven financial pattern that previously minted over 80,000 new millionaires. He believes a small $900 investment could turn into a $108,000 windfall within 12 months—and this may be the last chance for everyday investors to catch it. | Paradigm Press (Ad)Integrated Biopharma Inc (INBP)August 31, 2024 | investing.comIntegrated BioPharma, Inc. (INBP)July 19, 2024 | finance.yahoo.comIntegrated BioPharma Reports Results for its Quarter Ended December 31, 2023February 12, 2024 | finance.yahoo.comKBI Biopharma and Argonaut form drug manufacturing allianceJanuary 17, 2024 | msn.comKBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug ...January 16, 2024 | businesswire.comSee More Headlines INBP Stock Analysis - Frequently Asked Questions How have INBP shares performed this year? Integrated BioPharma's stock was trading at $0.3297 at the beginning of the year. Since then, INBP stock has decreased by 15.1% and is now trading at $0.28. How were Integrated BioPharma's earnings last quarter? Integrated BioPharma Inc. (OTCMKTS:INBP) posted its quarterly earnings results on Wednesday, May, 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The business earned $13.95 million during the quarter. Integrated BioPharma had a trailing twelve-month return on equity of 6.36% and a net margin of 2.37%. How do I buy shares of Integrated BioPharma? Shares of INBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Integrated BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated BioPharma investors own include GSK (GSK), Invitae (NVTA), Exxon Mobil (XOM), Autodesk (ADSK), Adaptive Biotechnologies (ADPT), Analog Devices (ADI) and Adaptimmune Therapeutics (ADAP). Company Calendar Last Earnings5/14/2025Today8/10/2025Next Earnings (Estimated)9/18/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:INBP CIK1016504 Webwww.integratedbiopharma.com Phone(973) 926-0816Fax973-926-1735Employees150Year Founded1995Profitability EPS (Trailing Twelve Months)$0.04 Trailing P/E Ratio7.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$110 thousand Net Margins2.37% Pretax Margin3.55% Return on Equity6.36% Return on Assets4.84% Debt Debt-to-Equity RatioN/A Current Ratio3.72 Quick Ratio1.70 Sales & Book Value Annual Sales$50.32 million Price / Sales0.17 Cash Flow$0.04 per share Price / Cash Flow6.32 Book Value$0.64 per share Price / Book0.44Miscellaneous Outstanding Shares30,980,000Free Float10,160,000Market Cap$8.67 million OptionableNot Optionable Beta0.80 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:INBP) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Integrated BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Integrated BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.